Breakthrough Dyspnea Fentanyl Study in Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Advanced CancersDyspnea
Interventions
DRUG

Fentanyl

Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.

OTHER

Placebo

Normal saline 0.9% preservative free SQ 15 minutes before walk test.

OTHER

Walking Tests

6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.

BEHAVIORAL

Questionnaires

Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01515566 - Breakthrough Dyspnea Fentanyl Study in Cancer Patients | Biotech Hunter | Biotech Hunter